National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Pheochromocytoma Treatment (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 01/03/2008



Purpose of This PDQ Summary






General Information






Cellular Classification






Stage Information







Treatment Option Overview






Localized Benign Pheochromocytoma






Regional Pheochromocytoma






Metastatic Pheochromocytoma






Recurrent Pheochromocytoma






Get More Information From NCI






Changes to This Summary (01/03/2008)






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Report to Nation Finds Declines in Cancer Incidence, Death Rates

High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

The Nation's Investment in Cancer Research FY 2009

Past Highlights
You CAN Quit Smoking Now!
Treatment Option Overview

Following the diagnosis of pheochromocytoma, medical management should be initiated with phenoxybenzamine (or alpha-1 adrenergic receptor antagonists, such as prazosin) to block alpha-adrenergic activity. Diuretics should not be used, and re-expansion of plasma volume may be accomplished by liberal salt or fluid intake. Low doses of a beta blocker such as propranolol are useful adjuncts to control blood pressure and cardiac tachyarrhythmias, but only after alpha blockade is established. Labetalol, an alpha- and beta-adrenergic blocker, has also been shown to be effective in the control of blood pressure and symptoms of pheochromocytoma. The use of combined alpha- and beta-adrenergic blockers or calcium antagonists can be continued on a long-term basis when the tumor is unresectable. For more refractory cases, or when severe and prolonged hypertension results from malignant disease, alpha-methyl-para-tyrosine is effective by inhibiting catecholamine synthesis.[1-3] This drug can decrease circulating catecholamines by 80% and alleviate many disease-related symptoms.[1-4]

References

  1. Manger WM, Gifford RW: Pheochromocytoma. New York: Springer-Verlag, 1977. 

  2. Young JB, Landsberg L: Catecholamines and the adrenal medulla: pheochromocytoma. In: Wilson JD, Foster DW, Kronenberg HM, et al., eds.: Williams Textbook of Endocrinology. 9th ed. Philadelphia, Pa: W.B. Saunders Company, 1998, pp 705-716. 

  3. Bravo EL, Gifford RW Jr: Current concepts. Pheochromocytoma: diagnosis, localization and management. N Engl J Med 311 (20): 1298-303, 1984.  [PUBMED Abstract]

  4. Bravo EL: Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev 15 (3): 356-68, 1994.  [PUBMED Abstract]

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov